What Does it Really Cost to Develop a New Treatment? A Brief Review of Drug Development Metrics Kenneth I Kaitin, Ph.D. Director, Tufts Center for the Study of Drug Development Prof. of Medicine, Prof. of Pharmacology & Exp. Therapeutics ASENT Annual Meeting Dinner Session Bethesda, MD, March 4, 2010 The Drug Development Pathway Basic Research Prototype Design or Discovery Preclinical Development IND Filing Phase I Phase II Clinical Development Phase III NDA/BLA Submission FDA Review/ Approval & Launch Phase IV, PMS, Life Cycle Management Clinical and Approval Times Vary Across Therapeutic Classes, 2003-07 7.9 Antineoplastic Neuropharmacologic 0.8 7.1 Anesthetic/Analgesic 1.4 5.2 AIDS Antiviral 5.2 0 1.7 0.6 6.9 5.8 Years Clinical Phase * excludes AIDS antivirals Source: Kaitin, Clin Pharmacol Ther, 2010;87:356-361 http://www.nature.com/clpt/journal/v87/n3/full/clpt2009293a.html 8.4 7.7 1.7 6.0 Cardiovascular 8.4 1.9 6.5 Antiinfective* 8.8 1.7 7.0 Endocrine 8.7 Approval Phase 10 Overall Clinical Approval Success Rate for NCEs has Dropped to 16% 23.9% Sys. Antiinfective 20.4% Musculoskeletal 19.4% Oncology/Immunology 9.4% GI/Metabolism 8.7% Cardiovascular 8.2% Neuropharmacologic 0 Clinical Approval Success Rate Source: DiMasi et al, Clin Pharmacol Ther, 2010;87:272-277 http://www.nature.com/clpt/journal/v87/n3/full/clpt2009295a.html 27 Capitalized Cost per Approved Biotech Product is Similar to that for Pharma 1500 1,318 Millions of 2005 Dollars 1,241 879 626 615 439 0 Non-Clinical Clinical Biotech Pharma (Time Adjusted) Source: DiMasi & Grabowski, Managerial Decision Econ, 2007;28:469-479 Total Costs Time Adjusted Capitalized Clinical Costs by Therapeutic Area 1000 $849 Millions of 2005 Dollars $741 $750 $792 $604 0 Anesth/Analg Cardiovascular Source: DiMasi et al, Drug Info J, 2004;38:211-223 All Antiinfective CNS Global Pharma Sales in 2008 by Therapeutic Category Cardiovascular $84.7 bil $78.0 bil CNS Cancer $59.9 bil Antiinfectives $43.8 bil $34.6 bil Respiratory Diabetes Inflammation $23.9 bil $21.7 bil Vaccines $19.1 bil Hormone Control $18.9 bil Gastrointestinal Hematology $17.1 bil $12.0 bil Source: Lehman Brothers, Sept 2008; in Parexel Statistical Sourcebook 2008-2009 10.3% of Global Market Drivers of Rising R&D Costs u Chronic and complex indications u Clinical trial size u Protocol design complexity u Patient recruitment/retention u High cost discovery/research tools u Regulatory demands u Market oriented studies u Late-stage attrition New Drug Approvals Are Not Keeping Pace with Rising R&D Spending 52 60 39 45 30 26 New Drug Approvals 13 15 0 1963 1968 1973 1978 1983 1988 1993 * Trend line is 3-year moving average; R&D expenditure adjusted for inflation Source: Kaitin, Clin Pharmacol Ther, 2010;87:356-361 http://www.nature.com/clpt/journal/v87/n3/full/clpt2009293a.html 1998 2003 0 2008 R&D Expenditures (Billions of 2008$) New Drug Approvals R&D Expenditures Tufts Center for the Study of Drug Development Tufts University, Boston, Massachusetts, USA Kenneth I Kaitin, Ph.D. Director Professor of Medicine Professor of Pharmacology & Exp. Therapeutics Website http://csdd.tufts.edu Email kenneth.kaitin@tufts.edu